上海家化联合股份有限公司 独立董事独立性 上海家化联合股份有限公司董事会 关于 2024 年度独立董事独立性情况的专项评估意见 根据《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》、《上 海证券交易所上市公司自律监管指引第 1 号--规范运作》等要求，公司董事会 就公司在任独立董事肖立荣、冯国华、夏海通的独立性情况进行评估并出具如下 专项意见: 经核查公司独立董事肖立荣、冯国华、夏海通的任职经历以及签署的相关自 查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股 东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍 其进行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理 办法》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》中对独立 董事独立性的相关要求。 上海家化联合股份有限公司董事会 2025年4月23日 ...

Financial Performance - The net profit attributable to shareholders for 2024 is -833,092,522.20 CNY, a decrease of 266.60% compared to the previous year's profit of 500,049,003.38 CNY[6]. - Operating revenue for 2024 is 5,678,512,025.49 CNY, representing a 13.93% decline from 6,597,599,900.71 CNY in 2023[20]. - The basic earnings per share for 2024 is -1.24 CNY, a decrease of 265.33% compared to 0.75 CNY in 2023[21]. - The company's consolidated revenue for the reporting period was CNY 5.68 billion, a year-on-year decrease of 13.9%[30]. - The net profit attributable to shareholders for 2024 was CNY -830 million, a year-on-year decline of 266.6%[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -840 million, a year-on-year decrease of 366.4%[30]. - The company recognized an asset impairment provision of CNY 610 million related to goodwill from previous acquisitions of infant care and maternal feeding product businesses[30]. - The company reported a net loss of approximately CNY 714.30 million for the Abundant Merit Limited subsidiary, which focuses on infant feeding tools and care products[67]. Cash Flow and Assets - The net cash flow from operating activities increased to 273,196,710.98 CNY, a 164.86% rise from 103,147,826.31 CNY in 2023[20]. - Total assets decreased by 15.22% to 9,944,442,518.04 CNY from 11,729,795,966.33 CNY in 2023[20]. - The company's cash and cash equivalents decreased by 41.42% to 550,466,054.78, mainly due to increased cash outflows from investment and financing activities[63]. - Accounts receivable decreased by 33.30% to 865,815,125.09, attributed to strategic adjustments impacting current revenue[63]. - The company's goodwill decreased by 28.81% to approximately CNY 1.49 billion, mainly due to significant performance declines in overseas operations leading to impairment losses[64]. Strategic Adjustments and Market Challenges - The company faced significant challenges in overseas markets, including low birth rates and increased competition, impacting revenue and gross profit[22]. - Strategic adjustments, including reducing inventory in department stores and transitioning to a self-operated model for online distributors, negatively affected current revenue and profits[22]. - The company anticipates that the strategic adjustments will benefit its long-term sustainable development despite the short-term negative impacts[22]. - The company plans to enhance its R&D investment and focus on core markets such as the UK and the US to improve brand influence through precise marketing[32]. Revenue Breakdown - The personal care segment generated revenue of approximately ¥2.38 billion, with a gross margin of 63.59%, an increase of 2.57 percentage points year-over-year[51]. - The beauty segment reported revenue of approximately ¥1.05 billion, with a gross margin of 69.67%, a decrease of 2.68 percentage points year-over-year[51]. - The overseas revenue amounted to approximately ¥1.42 billion, with a gross margin of 48.32%, down by 3.02 percentage points year-over-year[52]. - Online sales contributed approximately ¥2.54 billion, with a gross margin of 63.53%, a decrease of 9.66% year-over-year[52]. - Offline sales were approximately ¥3.14 billion, with a gross margin of 52.78%, down by 16.97% year-over-year[52]. Research and Development - Research and development expenses increased by 3.1% to CNY 150 million[30]. - The company employed 201 R&D personnel, accounting for 4.66% of total employees, with a significant portion holding master's degrees[59]. - The company has developed a skin surface AGEs fluorescence probe for real-time, quantifiable detection of skin glycation products, enhancing its product offerings in skin health[79]. - The company launched new products including the Six God Deodorizing and Itch Relief Flower Water, featuring proprietary technology for odor removal and skin soothing[81]. Governance and Compliance - The board of directors consists of 7 members, including 3 independent non-executive directors, ensuring diverse expertise[113]. - The independent directors attended all 8 board meetings in 2024, demonstrating active participation in governance[114]. - The company has established a comprehensive risk management system, identifying key control points and enhancing internal control processes to prevent risks[120]. - The company has committed to addressing any potential conflicts of interest arising from related party transactions[124]. Sustainability and Social Responsibility - The company invested 3.6 million RMB in environmental protection during the reporting period[161]. - The company achieved significant energy savings through various measures, including a total of 1,190 MWh saved from air conditioning and wastewater treatment improvements[164]. - The company has engaged in various charitable activities, including donations to support autism rehabilitation and education[167]. - The company has a commitment to sustainable development, as detailed in its 2024 Sustainability Report available on the Shanghai Stock Exchange website[168]. Financial Products and Investments - The company has entrusted a total of 2,300,000,000.00 RMB in bank wealth management products, with an outstanding balance of 2,250,000,000.00 RMB[187]. - The company has multiple bank wealth management products with expected annualized returns ranging from 3,443,284.93 RMB to 10,681,565.75 RMB[187]. - The financial products are primarily funded through self-owned capital, reflecting a conservative funding strategy[188][189]. Employee and Management - The total number of employees in the parent company is 1,138, while the total number of employees in major subsidiaries is 3,173, resulting in a combined total of 4,311 employees[142]. - The company has a performance evaluation system that will be continuously optimized in 2024, linking variable compensation to company performance, departmental performance, and individual assessments[143]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 12.248 million yuan[130].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,703,607,733.01, a decrease of 10.59% compared to CNY 1,905,398,114.42 in the same period last year[4] - Net profit attributable to shareholders was CNY 217,134,362.72, down 15.25% from CNY 256,207,190.53 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 34.49%, amounting to CNY 192,186,990.60 compared to CNY 293,382,590.79 in the previous year[4] - Basic and diluted earnings per share were both CNY 0.32, a decrease of 15.79% from CNY 0.38 in the previous year[5] - Operating profit for Q1 2025 was CNY 232,529,809.90, down 14.7% from CNY 272,485,558.68 in the same period last year[20] - The total comprehensive income for Q1 2025 was CNY 256,245,001.31, compared to CNY 230,653,584.01 in Q1 2024, reflecting a growth of 11.1%[21] Cash Flow and Assets - The net cash flow from operating activities increased by 7.96% to CNY 615,569,231.56, up from CNY 570,208,886.78 in the same period last year[4] - Cash and cash equivalents as of March 31, 2025, were RMB 642,789,403.39, up from RMB 550,466,054.78 at the end of 2024[13] - The net cash flow from operating activities in Q1 2025 was CNY 615,569,231.56, an increase of 7.9% compared to CNY 570,208,886.78 in Q1 2024[24] - The company reported a net cash outflow from investing activities of CNY -349,753,889.53 in Q1 2025, compared to CNY -5,279,450.36 in Q1 2024[24] - Cash and cash equivalents at the end of Q1 2025 totaled CNY 635,037,361.20, down from CNY 1,332,084,785.93 at the end of Q1 2024[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,415,987,751.19, an increase of 4.74% from CNY 9,944,442,518.04 at the end of the previous year[5] - Total current assets amounted to RMB 5,322,361,912.63, slightly up from RMB 5,261,900,533.94 at the end of 2024[14] - Total non-current assets increased to RMB 5,093,625,838.56 from RMB 4,682,541,984.10 at the end of 2024[15] - Total liabilities increased to RMB 3,565,257,418.71 from RMB 3,252,691,647.92 at the end of 2024[15] - Shareholders' equity attributable to shareholders was CNY 6,850,730,332.48, up 2.38% from CNY 6,691,750,870.12 at the end of the previous year[5] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,276[9] - The company held 6,143,072 shares in its repurchase account, accounting for 0.91% of the total share capital[11] Costs and Expenses - Total operating costs for Q1 2025 were RMB 1,502,972,403.47, down 5.8% from RMB 1,595,257,754.22 in Q1 2024[19] - Operating costs included RMB 623,462,399.64 for cost of goods sold, a decrease from RMB 699,901,352.07 in the previous year[19] - The company incurred research and development expenses of CNY 38,739,667.60 in Q1 2025, an increase from CNY 34,862,844.43 in Q1 2024[20] Non-Recurring Items - Non-recurring gains and losses totaled CNY 24,947,372.12, after accounting for tax effects of CNY 3,980,758.19[7] - The decline in net profit was primarily due to adjustments in pricing strategies and inventory optimization, which affected revenue and gross profit margins[7] - The company reported a significant increase in other comprehensive income, totaling CNY 39,110,638.59 in Q1 2025, compared to a loss of CNY -25,553,606.52 in Q1 2024[20]

证券代码：600315 证券简称：上海家化 公告编号：临 2025-020 上海家化联合股份有限公司 关于 2024 年度计提商誉减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海家化联合股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开 八届二十五次董事会，审议通过了《关于计提商誉减值准备的议案》。本议案无 需提交股东大会审议。现将本次计提商誉减值准备的具体情况公告如下： 一、本次计提减值准备概述 根据《企业会计准则第 8 号—资产减值》的相关规定以及公司会计政策等相 关规定，经过第三方专业评估公司的评估与测算，并基于谨慎性原则，公司于 2024 年度计提海外婴童护理、母婴喂养业务商誉减值准备，共计 6.13 亿元。 二、计提商誉减值准备情况 （一）商誉形成情况 根据公司六届十三次董事会及 2017 年第一次临时股东大会有关决议，公司 于 2017 年 12 月 27 日以现金方式收购了 Cayman A2,Ltd.的 100%股权和相关股东 债权。Cayman A2 下属经营实体 ...

3、公司实施员工持股计划，建立和完善劳动者与所有者的利益共享机制， 使员工利益与公司长远发展更紧密地结合，有利于进一步提升公司治理水平，完 善公司薪酬激励机制，提高员工的凝聚力和公司竞争力，充分调动员工积极性和 创造性，实现企业的长远可持续发展。 特此意见。 上海家化联合股份有限公司 董事会薪酬与考核委员会 关于公司 2025 年员工持股计划（草案）的意见 1、公司不存在《关于上市公司实施员工持股计划试点的指导意见）》（以 下简称"《指导意见》"）等法律、法规、规范性文件规定的禁止实施员工持股 计划的情形；《上海家化联合股份有限公司 2025 年员工持股计划（草案）》及 摘要的内容符合《公司法》、《中华人民共和国证券法》（以下简称"《证券法》"）、 《指导意见》等有关法律、法规及规范性文件以及《公司章程》的规定，不存在 损害公司及全体股东利益的情形。 2、本次员工持股计划拟定的持有人均符合《指导意见》及其他法律、法规、 规范性文件规定的条件，符合本次员工持股计划规定的参加对象的确定标准，其 作为本次员工持股计划持有人的主体资格合法、有效，亦不存在摊派、强行分配 等方式强制员工参与本次员工持股计划的情形；公司不 ...

证券简称：上海家化 证券代码：600315 上海家化联合股份有限公司 2025 年员工持股计划 （草案）摘要 二〇二五年四月 上海家化 2025 年员工持股计划（草案）摘要 声明 本公司及董事会全体成员保证本持股计划不存在虚假记载、误导性陈述或重 大遗漏，并对其真实性、准确性、完整性承担法律责任。 1 上海家化 2025 年员工持股计划（草案）摘要 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 1、本持股计划系公司依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《关于上市公司实施员 工持股计划试点的指导意见》（以下简称"《指导意见》"）等有关法律法规、规 章及其他规范性文件和《公司章程》的规定制定。 2、本持股计划遵循公司自主决定、员工自愿参加的原则，不存在摊派、强 行分配等强制员工参加本持股计划的情形。 3、本持股计划的参加对象为对公司整体业绩和中长期发展具有重要作用和 影响的公司（含下属子公司）董事（不含独立董事，下同）、高级管理人员、中 层管理人员及骨干员工。参加本次持股计划的总人数预计不超过45人（不含预留 份额持有人），其中董 ...

证券代码：600315 证券简称：上海家化 公告编号：临 2025-016 上海家化联合股份有限公司 关于 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上市公司行业信息披露指引第十三号——化工》的要 求、现将公司 2025 年第一季度主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 产量(支) | 销量(支) | 营业收入（元） | | --- | --- | --- | --- | | 个护 | 76,653,970 | 90,284,920 | 791,405,044.50 | | 美妆 | 12,668,528 | 20,067,136 | 328,671,629.87 | | 创新 | 21,553,749 | 22,193,350 | 232,993,523.08 | | 海外 | 25,034,211 | 22,331,347 | 347,300,376.37 | 注：个护（含六神、美加净品牌）、美妆（含玉泽、佰草 ...

上海家化联合股份有限公司 2024 年度控股股东及其他关联方占用资金情况专项报告 关于上海家化联合股份有限公司 控股股东及其他关联方占用资金情况专项报告 普华永道中天特审字(2025)第0305号 (第一页,共二页) 上海家化联合股份有限公司董事会: 我们审计了上海家化联合股份有限公司(以下简称"贵公司")2024 年 12 月 31 日的合并及公司资产负债表、2024年度合并及公司利润表、合并及公司 现金流量表、合并及公司股东权益变动表和财务报表附注(以下合称"财务报 表"),并于2025年4月23日出具了报告号为普华永道中天审字(2025)第10022 号的无保留意见审计报告。财务报表的编制和公允列报是贵公司管理层的责任, 我们的责任是在按照中国注册会计师审计准则执行审计工作的基础上对财务报 表整体发表审计意见。 普华永道 在对上述财务报表执行审计的基础上,我们对后附的截至 2024年12月 31 日止年度贵公司控股股东及其他关联方非经营性资金占用及其他关联资金往来 情况汇总表(以下简称"情况表")执行了有限保证的签证业务。 普华永道中天特审字(2025)第0305号 (第二页,共二页) 上海家化联合股份 ...

公司代码：600315 公司简称：上海家化 上海家化联合股份有限公司 2024年度内部控制评价报告 上海家化联合股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导 ...

上海家化联合股份有限公司 审计与风险管理委员会履职报告 上海家化联合股份有限公司 审计与风险管理委员会 2024 年度履职情况报告 一、审计与风险管理委员会基本情况 公司第八届董事会审计与风险管理委员会由独立董事肖立荣、冯国华、夏海 通及董事邓明辉 4 名成员组成，肖立荣担任主任委员。 审计与风险管理委员会成员均具有能够胜任委员会工作职责的专业知识和 工作经验，保证足够的时间和精力履行委员会的工作职责。2024 年度，审计与 风险管理委员会委员凭借丰富的行业经验及专业审计、会计知识，在监督及评估 外部审计机构的工作、指导公司内部审计、审阅公司财务报告等方面向董事会提 出了专业意见，在公司审计与风险管理等方面发挥了重要作用。 2、指导内部审计工作 二、2024 年度会议召开情况 2024 年度审计与风险管理委员会共召开六次会议，会议根据《公司章程》、 《董事会审计与风险管理委员会工作细则》的规定召开，主要审议并听取了年度 审计工作安排、定期财务报告、内部控制、利润分配方案、日常关联交易、续聘 会计师事务所、风险管理工作等事项，其中重点持续关注了公司风险管理、专项 审计、财务及流程合规性等工作，完善了公司风控体系 ...